Drugs / Pafuramidine
Pafuramidine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00408369 | Nov 2006 → Nov 2007 | — | Immtech Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00803933 | Feb 2003 → Feb 2004 | human African trypanosomiasis | Immtech Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00802594 | Aug 2001 → Aug 2002 | human African trypanosomiasis | Immtech Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00302341 | May 2006 → Dec 2008 | HIV infectious disease, pneumocystosis | Immtech Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00619346 Comparator | Nov 2007 → Feb 2009 | — | Immtech Pharmaceuticals, Inc | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pafuramidine | “Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies.” PMID 26881924 ↗ Feb 2016 |
| Known as | DB289 | “The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to...” NCT00302341 ↗4“Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects” NCT00619346 ↗ “Pafuramidine maleate (DB289), 100 mg BID orally” NCT00803933 ↗ |
| Known as | Pafuramidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL319669 ↗ |
| Known as | pafuramidine maleate | “The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to...” NCT00302341 ↗ |
| Modality | Small molecule | — CHEMBL319669 ↗ |
| Route | Oral | “Oral tablet, 100 mg bid, 14 days” NCT00302341 ↗ |